Arcutis gets FDA approval for ZORYVE (roflumilast) cream 0.3% for plaque psoriasis; draws $125M in debt

Arcutis Biotherapeutics, Inc.

FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis, including intertriginous areas, in patients 12+.
First and only topical PDE4 inhibitor approved for plaque psoriasis; once-daily, steroid-free, no duration limit.
Commencing $125M drawdown of Tranche B term loans from SLR Investment Corp. to fund launch and pipeline.
Product expected to be available via wholesalers and dermatology pharmacies by mid-August 2022.
DERMIS-1/2 Phase 3 trials: 42% and 37% IGA success at Week 8 (P<0.0001); itch reduction as early as Week 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.